Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...

LONDON: Cancer treatment follows a familiar pattern: Doctors spot symptoms, diagnose the disease and start treatment. But ...

Baird initiated with Outperform at $113, calling Grail "a commercial-stage healthcare company focused on multi-cancer early ...

NG Biotech manufactured the assays in France, with Hardy Diagnostics serving as the exclusive distributor in the US.

MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial ...

Commercial adoption of the Galleri multi-cancer early detection test remained a bright spot, with more than 185,000 tests sold during the 2025 fiscal year. U.S. Galleri revenue grew 26% annually to ...

We recently published 10 Market Winners With Stunning Gains. Ondas Inc. (NASDAQ:ONDS) was one of the best performers on Wednesday. Ondas saw its share prices jump by 10.15 percent on Wednesday to ...

Integration of Pierce Aerospace’s Remote ID capabilities into UNIFY.C2 strengthens real-time identification, tracking, ...

Markel, the insurance division of Markel Group Inc., has announced a new partnership with Upfort aimed at strengthening cybersecurity resources for ...

Trusted by senior executives, international families, government representatives and professional athletes, Echelon Health is a specialist preventive health assessment practice focused exclusively on ...

Owners want fewer platforms to manage, faster response times, and clearer proof of compliance — especially in ...